OTCM
CHHE
Market cap6kUSD
Nov 10, Last price
0.00USD
Name
China Health Industries Holdings Inc
Chart & Performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Operating through its various subsidiaries, China Health Industries Holdings, Inc. specializes in the production and distribution of a comprehensive array of health-oriented goods. Its product portfolio features numerous hemp-derived items, including hemp oil, protein powders, polypeptides, and a selection of skincare solutions like essence repair lotions, revitalizing essences, anti-aging brightening eye creams, and nourishing creams designed to combat signs of aging. The company also supplies dietary supplements, such as the QunLe brand's Sailuozhi soft capsules, which combine frog oil, soybean isoflavone, procyanidine, and vitamin E to help reduce freckles and enhance skin moisture. Another key offering is the Kindlink brand's propolis and black ant capsules, formulated with propolis, black ant, acanthopanax, and astragalus root. Beyond these, China Health Industries provides a range of health products addressing specific concerns like acne treatment, relief from eye strain, boosting bone density, improving memory, combating nutritional anemia and chloasma, promoting digestive health and lead detoxification, bolstering immunity, alleviating physical fatigue, and diminishing chloasma, alongside essential iron and multi-vitamin and mineral supplements. Additionally, the firm is involved in the manufacturing and sale of various medical drugs. The distribution of its extensive product line is primarily managed through a network of sales agents. China Health Industries Holdings, Inc. maintains its base of operations in Harbin City, People's Republic of China.
IPO date
Dec 01, 2004
Employees
45
Domiciled in
CN
Incorporated in
US
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|
| 2023‑06 | 2022‑06 | 2021‑06 | 2020‑06 | 2019‑06 | 2018‑06 | 2017‑06 | |
| Income | |||||||
Revenues | |||||||
Cost of revenue | |||||||
Unusual Expense (Income) | |||||||
NOPBT | |||||||
NOPBT Margin | |||||||
Operating Taxes | |||||||
Tax Rate | |||||||
NOPAT | |||||||
Net income | |||||||
Dividends | |||||||
Dividend yield | |||||||
Proceeds from repurchase of equity | |||||||
BB yield | |||||||
| Debt | |||||||
Debt current | |||||||
Long-term debt | |||||||
Deferred revenue | |||||||
Other long-term liabilities | |||||||
Net debt | |||||||
| Cash flow | |||||||
Cash from operating activities | |||||||
CAPEX | |||||||
Cash from investing activities | |||||||
Cash from financing activities | |||||||
FCF | |||||||
| Balance | |||||||
Cash | |||||||
Long term investments | |||||||
Excess cash | |||||||
Stockholders' equity | |||||||
Invested Capital | |||||||
ROIC | |||||||
ROCE | |||||||
| EV | |||||||
Common stock shares outstanding | |||||||
Price | |||||||
Market cap | |||||||
EV | |||||||
EBITDA | |||||||
EV/EBITDA | |||||||
Interest | |||||||
Interest/NOPBT | |||||||